Lisa Berdan, PA-C
Director, Global Outcomes Commercial Megatrials
Lisa Berdan has been involved in cardiovascular (CV) megatrials for over 20 years and has successfully developed an industry-recognized operational business unit including over 70 clinical operations professionals who are dedicated to these large international programs in acute coronary syndromes, atrial fibrillation, chronic coronary artery disease, diabetes, and peripheral arterial disease. These trials typically have at least 5,000 patients enrolled in multiple countries and include ASCEND HF, EXSCEL, IMPROVE IT, ROCKET AF, TECOS, TRACER, TRILOGY, Roche dal-O2 and AZ-PAD.
Berdan is responsible for leading the strategy, growth, and expansion of this significant area of business as well as overseeing the operational implementation of all commercial (industry-funded) CV megatrials. She represents the DCRI and participates in organization-wide initiatives including 1) expanding collaboration with our global ARO partners, 2) collaborating with leadership to develop site-focused clinical research training programs and expanding global site relationships and networks, and 3) advising and collaborating with Brazilian Clinical Research Institute. She also provides senior mentoring, advice, and support to the DCRI Business Development and Clinical Operations groups.